- Research Areas
- Dynamic Brain Circuits and Connections in Health and Disease
- Core facilities
- Research administration services
- Funding Opportunities
- DMCBH Membership
- News & Events
- Brain Matters Newsletter
- Neuroscience Research Colloquium
You are hereNewsroom
Walking the Walk to end MS
Every year, the UBC Hospital MS Clinic's UBC MS Remyelinators get bigger and better.
The MS Walk, an annual fundraising event engaging more than 40,000 Canadians across the country, highlights the cause at the center of everything the UBC Hospital MS Clinic at the Djavad Mowafaghian Centre for Brain Health does. This year the team, the UBC MS Remyelinators, was comprised of 85 researchers, clinicians, trainees (post-docs, master and graduate students, clinical fellows, residents), and family and friends who joined the MS Walk.
This year's MS Walk was the team's seventh opportunity to be part of this community-based effort to end MS. This year, the UBC MS Remyelinators raised $9,385; funds raised as part of the MS Walk help to advance research into the cause and cure for MS, a disease that affects 100,000 people in Canada.
Remyelination: The repair of damaged myelin. Myelin repair occurs spontaneously in MS but very slowly. Research is currently underway to find a way to speed the healing process.
The MS clinic at the Djavad Mowafaghian Centre for Brain Health is led by a world-renowned MS clinical research team. The clinic, which cares for 80 to 90 per cent of MS patients in BC, has a global reputation for its emphasis on treatment, education and translational research. The clinic is a national clinical trial centre for new pharmaceutical therapies and is home to the world’s largest MS database of over 7500 patients, many of whom have been followed for over 25 years.
The MS research team is comprised of specialists in pharmaceutical and interventional therapies, imaging, genetics, epidemiology, pathology and immunology.
The MS research and clinical care team are a tight-knit community with a shared ambition to help patients, provide better treatment options for people with MS, and enhance their overall quality of life. Our UBC MS Remyelinators and the research and clinical team at the Centre continue to strive for the finish line and achieve the ultimate goal of finding an end to MS.